{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.6","upperLimit":"62.7","value":"56.4"},{"groupId":"OG001","lowerLimit":"39.0","upperLimit":"52.2","value":"45.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}],"units":"Participants"}],"description":"OS30m was defined as the probability of a participant being alive at 30 months from date of randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG000","title":"Dacomitinib"},{"description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, for maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG001","title":"Gefitinib"}],"paramType":"NUMBER","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Up to 30 months from date of randomization","title":"OS at 30 Months (OS30m)","type":"SECONDARY","unitOfMeasure":"probability of survival"}